Good MorningEquity markets slowed their declines, but new lows were set on Thursday. The move lower may have ended, but there is a risk that it will deepen before the bottom is hit. The market is repricing the odds of FOMC rate cuts, which will have far-reaching ramifications for stocks. The takeaway is that the outlook for earnings growth in the 2nd half is flawed.
The best target for solid support for the S&P 500 is near 4,800 and the prior all-time highs. That level is a significant pivot crossed earlier this year that has yet to be confirmed as support. If support is confirmed, new all-time highs are likely by the end of the year. If not, this market could sell off for several months and be down 20% to 30% from its highs.
Featured: The big winner of Crypto week? (Ad) 
|
Markets | | |
As investors search for safe havens in volatile markets, bear market funds are gaining popularity as a diversified asset class designed to withstand exceptionally volatile markets. While bear market funds can be appealing during periods of economic downturn due to their potential to produce return... Read the Full Story |
|
From Our Partners | | Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity.
While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. | | Watch the Bitcoin Skimming strategy here |
|
Markets | | |
A new business cycle is underway for the United States economy, and the manufacturing sector could be in play. This time, it isn't only Wall Street pushing the bets forward but also the current administration's attempt to onshore some global steel and aluminum manufacturing jobs.
So far, markets ... Read the Full Story |
|
Markets | | |
Thinking about investing in PepsiCo? PepsiCo (NASDAQ: PEP) is the world’s 2nd largest consumer food company behind Nestle. It is the US's largest consumer food company, growing domestically and internationally. It is an attractive stock for many reasons.
The company's deeply rooted hi... Read the Full Story |
|
From Our Partners | | How to Collect Up To $5,917/mo From Trump's Made In USA Boom
Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America.
But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month.
Don't miss your chance to participate directly in America's industrial comeback. | | Watch Now to Learn How to Get Your First Check in 30 Days |
|
Markets | | |
In 2024, Tesla (NASDAQ: TSLA) finds itself navigating through a year filled with turbulence, starkly contrasting its historical performance as a leader in the electric vehicle and technology sectors. With shares plummeting, Tesla now holds the unfortunate title of being the worst-performing S&... Read the Full Story |
|
Stocks | | | The worst week for big technology stocks since the COVID crash in 2020 dragged Wall Street on Friday across the finish line of another losing week. The S&P 500 dropped 0.9% to close out its third straight losing week. That’s its longest such streak since September, before it broke into a romp th... Read the Full Story |
|
From Our Partners | Most traders guess. This system doesn’t.
Using his Momentum Indicator, one trader turned $15K into $150K in six months — stacking 20–30% daily gains. Now he’s sharing 3 stocks flashing BUY right now, plus a free report showing how to trade them. | | Claim your 3 stock picks + free momentum trading report |
|
Markets | | |
CSX Corporation (NASDAQ: CSX) is a leading North American freight railroad operator. The railroad and railway sub-sector operates within the broader transportation sector. CSX’s earnings report was recently released and exceeded market expectations in its first quarter of 2024. The company's... Read the Full Story |
|
Markets | | | European Union leaders on Thursday debated a new “European Competitiveness Deal” aimed at helping the 27-nation bloc close the gap with Chinese and American rivals amid fears the region's industries will otherwise be left behind for good.In a volatile geopolitical landscape redefined by the ongoing ... Read the Full Story |
|
Markets | | | European Union leaders on Thursday debated a new “European Competitiveness Deal” aimed at helping the 27-nation bloc close the economic production gap with Chinese and American rivals amid fears the region's industries will otherwise be left behind for good.In a volatile geopolitical landscape redef... Read the Full Story |
|
Markets | | | There was no shortage of stressors to the global economy when Ajay Banga took charge at the World Bank almost a year ago: inflation eating at nations drowning in debt, a once-in-a-generation pandemic, climate disasters and Russia's invasion of Ukraine. Factor in the Israel-Hamas war and rising tensi... Read the Full Story |
|
Markets | | | The head of the International Monetary Fund said Thursday that the world economy has proven surprisingly resilient in the face of higher interest rates and the shock of war in Ukraine and Gaza, but “there is plenty to worry about,″ including stubborn inflation and rising levels of government debt Read the Full Story |
|
Friday's Early Bird Stock Of The Day Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. | | View Today's Stock Pick |
|
